头颈癌中PD-L1检测方法的比较
Comparison of PD-L1 assays in head and neck carcinoma
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:3
分区:医学3区 / 病理学3区
发表日期:2024 Dec
作者:
Ji-Seon Jeong, Uiree Jo, Gyuheon Choi, Halim Song, Kyung-Ja Cho, Joon Seon Song
DOI:
10.1016/j.pathol.2024.06.006
摘要
程序性细胞死亡配体1（PD-L1）表达是头颈鳞状细胞癌免疫检查点抑制剂反应的预测生物标志物。鉴于PD-L1检测所用抗体和平台种类繁多，了解不同染色与评分方法的性能尤为重要。在阿斯兰医学中心对156例头颈黏膜鳞状细胞癌（HNmSCC）病例中，使用106个组织芯片（TMA）核心和50个全切片评估了PD-L1表达。评价采用三种标准化的PD-L1检测（22C3 pharmDx、SP263和28-8 pharmDx）以及一种实验室自主开发的检测（22C3 LDT），包括结合阳性评分（CPS）≥1、≥20和≥50，以及肿瘤阳性评分（TPS）≥1%、≥20%、≥50%的评估。在连续尺度上的一致性方面，CPS（组内相关系数ICC范围0.73-0.94）和TPS（ICC范围0.70-0.94）在TMA和全切片队列中表现良好至优异。不同临界值的分层分析显示大多数检测方法具有中等到良好的一致性（由Gwet的AC1分析）。使用22C3 pharmDx检测，PD-L1表达与肿瘤位置显著相关（CPS，p=0.014；TPS，p=0.033）。PD-L1检测方法之间存在显著一致性，表明其在HNmSCC中的潜在互换性。
Abstract
Programmed cell death-ligand 1 (PD-L1) expression is a predictive biomarker for response to immune checkpoint inhibitor in head and neck squamous cell carcinoma. Given the range of antibodies and platforms for PD-L1 testing, it is essential to understand the performance of different staining and scoring methods. PD-L1 expression in 156 head and neck mucosal squamous cell carcinoma (HNmSCC) cases at Asan Medical Center was assessed using 106 tissue microarray (TMA) cores and 50 whole slides. Three standardised PD-L1 assays (22C3 pharmDx, SP263, and 28-8 pharmDx) and one laboratory-developed test (22C3 LDT) were evaluated: the combined positive score (CPS) with ≥1, ≥20, and ≥50 cut-offs, and the tumour positive score (TPS) with ≥1%, ≥20%, ≥50% cut-offs. Concordance on a continuous scale among the assays was good to excellent for CPS [intraclass correlation coefficient (ICC) range 0.73-0.94] and TPS (ICC range 0.70-0.94) and in both TMA and whole slides cohorts. Stratification by variable cut-offs demonstrated moderate to good agreement among most assays, as analysed by Gwet's AC1. PD-L1 expression was significantly correlated with tumour location using the 22C3 pharmDx assay (CPS, p=0.014; TPS, p=0.033). Notable concordance was found among PD-L1 assays, suggesting their potential interchangeability in HNmSCC.